Vaccine News and Research

Latest Vaccine News and Research

First COVID-19 vaccine found to be safe, able to generate rapid immune response in phase 1 clinical trial

The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet.

22 May 2020

Different immune responses can occur in Covid-19, shows study

The human immune system is reactive to more than just the viral protein on which researchers have focused to date. This is relevant for tests and potential vaccines.

22 May 2020

New review analyzes evidence and strategies to manage the SARS-CoV-2 virus

How should orthopaedic surgeons respond to the COVID-19 pandemic? A review in The Journal of Bone & Joint Surgery analyzes evidence and strategies for managing the novel SARS-CoV-2 virus - including critical lessons from past pandemics.

22 May 2020

Americans' confidence in medical scientists has grown since the coronavirus outbreak

Americans' confidence in medical scientists has grown since the coronavirus outbreak first began to upend life in the United States, as have perceptions that medical doctors hold very high ethical standards, according to a new Pew Research Center report.

22 May 2020

New clinical trial to test treatment that targets overactive immune response to COVID-19

For some COVID-19 patients, the body's immune response may be as destructive as the virus that causes the disease.

22 May 2020

Changes in antibodies and RNA shedding during early SARS-CoV-2 infection

As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.

22 May 2020

IL-6 blocker use in severe COVID-19 increases risk of secondary infections

With many hundreds of thousands of deaths due to the current COVID-19 pandemic, there is a rush to find an effective vaccine or drug against the virus. A new study on the preprint server medRxiv* in May 2020 shows that the use of some biologically plausible drugs may be counterproductive, and care should be taken when trying out unproven therapies.

22 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Preparing to meet SARS-CoV-2 head-on with a panel of neutralizing antibodies

A new study published on the preprint server bioRxiv in May 2020 describes a panel of neutralizing antibodies that bind to multiple attachment sites on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 disease pandemic.

22 May 2020

Simple molecular 'switch' transforms autoimmunity drugs into powerful anti-cancer treatments

Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular "switch".

21 May 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

Computational immunology paves the way for SARS-CoV-2 peptide cocktail vaccine candidate

By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.

21 May 2020

COVID-19 in farmed Mink in the Netherlands

A new study published on the preprint server bioRxiv in May 2020 reports the development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in farmed mink in two locations in the Netherlands.

21 May 2020

KHN’s ‘What the Health?’: When it comes to COVID-19, states are on their own

At least so far, states that reopened their economies are not seeing a major spike in cases of COVID-19. But it remains unclear if that is because the coronavirus is not spreading, because the data is lagging or because the data is being manipulated.

21 May 2020

LLNL engineers address shortage of nasopharyngeal swabs for COVID-19

In this era of COVID-19, tracking the disease adequately enough to allow state and local officials to lift shelter-in-place orders and return to a semblance of normalcy in the absence of a vaccine will require widespread testing, according to medical experts.

21 May 2020

Producing virus-specific antibodies after COVID-19

In order to design effective vaccines for COVID-19, we need to understand our immune responses. News-Medical speaks to Professor Chen Dong to find out more.

21 May 2020

Bio-Techne and Kantaro Biosciences announce partnership to develop and scale production of COVID-19 serology test

Bio-Techne Corporation and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test.

From Bio-Techne 21 May 2020

Analysis: Get ready for the vaccine — they’re never simple

If there is a silver lining to the flawed U.S. response to the coronavirus pandemic, it is this: The relatively high number of new cases being diagnosed daily — upward of 20,000 — will make it easier to test new vaccines.

21 May 2020

Lattice light-sheet microscopy could help in drug and vaccine development

From testing drugs to developing vaccines, the close study of the immune system is key to improving real-world health outcomes. T-cells are integral to this research, as these white blood cells help tailor the body's immune response to specific pathogens.

21 May 2020

Lifesaving innovation for COVID-19 will increase the already existing racial inequalities

As is the case with most fatal diseases, coronavirus disease (COVID-19) is already taking a disproportionate toll on black Americans and other disadvantaged minorities.

20 May 2020

Vaccine News and Research

Latest Vaccine News and Research

First COVID-19 vaccine found to be safe, able to generate rapid immune response in phase 1 clinical trial

Different immune responses can occur in Covid-19, shows study

New review analyzes evidence and strategies to manage the SARS-CoV-2 virus

Americans' confidence in medical scientists has grown since the coronavirus outbreak

New clinical trial to test treatment that targets overactive immune response to COVID-19

Changes in antibodies and RNA shedding during early SARS-CoV-2 infection

IL-6 blocker use in severe COVID-19 increases risk of secondary infections

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

Preparing to meet SARS-CoV-2 head-on with a panel of neutralizing antibodies

Simple molecular 'switch' transforms autoimmunity drugs into powerful anti-cancer treatments

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Computational immunology paves the way for SARS-CoV-2 peptide cocktail vaccine candidate

COVID-19 in farmed Mink in the Netherlands

KHN’s ‘What the Health?’: When it comes to COVID-19, states are on their own

LLNL engineers address shortage of nasopharyngeal swabs for COVID-19

Producing virus-specific antibodies after COVID-19

Bio-Techne and Kantaro Biosciences announce partnership to develop and scale production of COVID-19 serology test

Analysis: Get ready for the vaccine — they’re never simple

Lattice light-sheet microscopy could help in drug and vaccine development

Lifesaving innovation for COVID-19 will increase the already existing racial inequalities

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in